A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Recruiting now · Phase 1/Phase 2

Conditions studied: Lymphoma, B-Cell, Lymphoma, T-Cell

In brief

The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.

Key facts

Study ID

NCT05463263

Run by

Step Pharma, SAS

People needed

180

Starts

2022-08-03

Expected to finish

2026-12-01

Last updated by the study team

2026-06-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Colorado Blood Cancer Institute — Denver, Colorado, United States (enrolling)
• Florida Cancer Specialists — Sarasota, Florida, United States (enrolling)
• Memorial Sloan Kettering — New York, New York, United States (enrolling)
• Hôpital Saint-Louis — Paris, Paris, France (enrolling)
• The Centre Léon Bérard — Lyon, France (enrolling)
• Institut Paoli Calmettes — Marseille, France (enrolling)
• CHU de Nantes — Nantes, France (enrolling)
• Institut Gustave Roussy — Villejuif, France (enrolling)
• University Hospitals of Leicester NHS Trust — Leicester, United Kingdom (enrolling)
• Imperial College / Clinical Trials Unit, Hammersmith Hospital — London, United Kingdom (enrolling)
• The Christie — Manchester, United Kingdom (enrolling)
• Nottingham City Hospital — Nottingham, United Kingdom (enrolling)
• Churchill Hospital — Oxford, United Kingdom (enrolling)
• Derriford Hospital — Plymouth, United Kingdom (enrolling)
• The Royal Marsden — Sutton, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.